8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: May 30, 2007

(Date of earliest event reported)

ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware	04-2743260
(State or other Jurisdiction of Incorporation)	(IRS Employer Identification Number)
0-20584
(Commission File Number)
22 Cherry Hill Drive Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978) 646-1400
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

On May 30, 2007, we elected Dr. Eric A. Rose as a member of our Board of Directors. Dr. Rose will serve as a Class II director until our 2009 annual meeting of stockholders and thereafter until his successor is duly elected and qualified. Dr. Rose has been granted a stock option to purchase 25,000 shares of our common stock, vesting annually over four years. The stock option has an exercise price of $11.27 equal to the closing price of our common stock on the date of grant, May 30, 2007. Although we expect that Dr. Rose will be appointed to serve on at least one committee of the board of directors, the committees on which he will serve have not been determined at this time.

Item 7.01 Regulation FD Disclosure.

A copy of the press release we issued announcing Dr. Rose’s election to our Board of Directors is set forth as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 7.01 and Item 9.01 below shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Number	Title
99.1	Press Release dated May 31, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABIOMED, Inc.

By:  /s/  Daniel J. Sutherby                    

        Daniel J. Sutherby

        Chief Financial Officer

Date: May 31, 2007

EXHIBIT INDEX

Number	Title
99.1	Press Release dated May 31, 2007.

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

ABIOMED APPOINTS ERIC A. ROSE, M.D., A LEADER IN

CIRCULATORY CARE, TO ITS BOARD OF DIRECTORS

Danvers, Mass., May 31, 2007—Abiomed, Inc. (NASDAQ: ABMD) announced today that Dr. Eric A. Rose has been appointed to its Board of Directors. Dr. Rose is an esteemed cardiothoracic surgeon, having authored or co-authored more than 300 peer-reviewed publications including articles on cardiovascular surgery, ventricular assist devices and cardiac transplantation. Dr. Rose has led the development of a premier Department of Surgery at Columbia University and has managed, investigated, and developed numerous complex medical technologies ranging from heart transplantation to novel approaches to treat Alzheimer’s disease and bioterrorism. He is currently on leave as Chairman of Columbia’s Department of Surgery, a position he held since 1994, and is serving as Chief Executive Officer and Chairman of the board of SIGA Technologies, Inc., a leading biotechnology firm addressing bioterrorist threats.

Dr. Rose co-founded TransTech Pharma (TTP), Inc., a pharmaceutical company focused on the discovery, development, and commercialization of therapeutics to treat a wide range of human diseases including cardiovascular disorders, central nervous system disorders, diabetes, obesity and cancer. Dr. Rose also serves as Executive Vice President for Life Sciences at MacAndrews and Forbes, Inc. He received his bachelor’s degree from Columbia College and his medical degree from Columbia University College of Physicians and Surgeons. His postgraduate training was in general surgery and cardiothoracic surgery at the Columbia Presbyterian Medical Center. Dr. Rose also holds three honorary doctoral degrees.

“It is an honor to join Abiomed’s distinguished Board of Directors and I look forward to contributing to Abiomed’s strategy focused on heart recovery,” said Dr. Rose.

“Dr. Rose is an expert in FDA trial design, has led multiple clinical trials in circulatory care and is widely respected as a pioneer in the use of ventricular assist devices. We are excited and proud to welcome him to Abiomed’s Board of Directors,” said Michael R. Minogue, Chairman, CEO and President of Abiomed.

Dr. Rose is a member of more than a dozen academic and professional societies and committees, and is a former President of the International Society for Heart and Lung Transplantation.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with

the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Contacts:

Daniel J. Sutherby Abiomed, Inc. Chief Financial Officer 978-646-1812 ir@abiomed.com Liza Heapes Abiomed, Inc. Media Relations 978-646-1668 mediarelations@abiomed.com

#